Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/361
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Sodium Chloride (Injection, Solution)
|
| dailymed-instance:dosage |
As directed by a
physician. Dosage is dependent upon the age, weight, and clinical
condition of the patient as well as laboratory determinations. Parenteral drug
products should be inspected visually for particulate matter and
discoloration prior to administration whenever solution and container
permit. Use of a final filter is recommended during administration of
all parenteral solutions, where possible. All injections in
VIAFLEX plastic containers are intended for intravenous administration
using sterile equipment. Additives may be
incompatible. Complete information is not available. Those additives
known to be incompatible should not be used. Consult with pharmacist, if
available. If, in the informed judgment of the physician, it is deemed
advisable to introduce additives, use aseptic technique. Mix thoroughly
when additives have been introduced. Do not store solutions containing
additives.
|
| dailymed-instance:descripti... |
3% and 5% Sodium
Chloride Injection, USP is a sterile, nonpyrogenic, hypertonic solution
for fluid and electrolyte replenishment in single dose containers for
intravenous administration. The pH may have been adjusted with
hydrochloric acid. It contains no antimicrobial agents. Composition,
ionic concentration, osmolarity, and pH are shown in Table 1. The VIAFLEX plastic
container is fabricated from a specially formulated polyvinyl chloride
(PL 146 Plastic). The amount of water that can permeate from inside the
container into the overwrap is insufficient to affect the solution
significantly. Solutions in contact with the plastic container can leach
out certain of its chemical components in very small amounts within the
expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts
per million. However, the safety of the plastic has been confirmed in
tests in animals according to USP biologicaltests for plastic
containers as well as by tissue culture toxicity studies.
|
| dailymed-instance:clinicalP... |
3% and 5% Sodium
Chloride Injection, USP has value as a source of water and electrolytes.
It is capable of inducing diuresis depending on the clinical condition
of the patient.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
None
known
|
| dailymed-instance:supply |
3% and 5% Sodium Chloride Injection, USP in VIAFLEX plastic container is available as
follows: Exposure of pharmaceutical products to heat should be minimized. Avoid excessive
heat. It is recommended the product be stored at room temperature
(25��C); brief exposure up to 40��C does not adversely affect the
product.<br/>Directions for Use
of VIAFLEX Plastic Container: Warning: Do not use plastic
containers in series connections. Such use could result in air
embolism due to residual air being drawn from the primary
container before administration of the fluid from the secondary
container is completed.<br/>To Open: Tear
overwrap down side at slit and remove solution container. Some
opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does
not affect the solution quality or safety. The opacity will
diminish gradually. Check for minute leaks by squeezing inner
bag firmly. If leaks are found, discard solution as sterility
may be impaired. If supplemental medication is desired, follow
directions below.<br/>Preparation for
Administration:<br/>To Add Medication: Warning: Additives may be
incompatible.<br/>To add
medication before solution administration:<br/>To add
medication during solution administration: Baxter Healthcare
Corporation Deerfield, IL 60015 USA Printed in USA
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:precautio... |
Clinical evaluation
and periodic laboratory determinations are necessary to monitor changes
in fluid balance, electrolyte concentrations, and acid base balance
during prolonged parenteral therapy or whenever the condition of the
patient warrants such evaluation. Caution must be
exercised in the administration of 3% and 5% Sodium Chloride Injection,
USP to patients receiving corticosteroids or corticotropin.<br/>Pregnancy:<br/>Teratogenic
Effects:<br/>Pediatric Use: Safety and
effectiveness of 3% and 5% Sodium Chloride Injection, USP in
pediatric patients have not been established by adequate and
well controlled trials, however, the use of sodium chloride solutions in the pediatric population is referenced in the
medical literature. The warnings, precautions and adverse
reactions identified in the label copy should be observed in the
pediatric population.<br/>Geriatric Use: Clinical
studies of 3% and 5% Sodium Chloride Injection, USP, did not
include sufficient numbers of subjects aged 65 and over to
determine whether they respond differently from younger
subjects. Other reported clinical experience has not identified
differences in responses between the elderly and younger
patients. In general, dose selection for an elderly patient
should be cautious, usually starting at the low end of the
dosing range, reflecting the greater frequency of decreased
hepatic, renal, or cardiac function, and of concomitant disease
or drug therapy. This drug
is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients
with impaired renal function. Because elderly patients are more
likely to have decreased renal function, care should be taken in
dose selection, and it may be useful to monitor renal function. Do not
administer unless solution is clear and seal is
intact.
|
| dailymed-instance:genericMe... |
Sodium Chloride
|
| dailymed-instance:fullName |
Sodium Chloride (Injection, Solution)
|
| dailymed-instance:adverseRe... |
Reactions which may
occur because of the solution or the technique of administration include
febrile response, infection at the site of injection, venous thrombosis
or phlebitis extending from the site of injection, extravasation and
hypervolemia. If an adverse
reaction does occur, discontinue the infusion, evaluate the patient,
institute appropriate therapeutic countermeasures, and save the
remainder of the fluid for examination if deemed necessary.
|
| dailymed-instance:warning |
3% and 5% Sodium
Chloride Injection, USP is strongly hypertonic and may cause vein
damage. 3% and 5% Sodium
Chloride Injection, USP should be used with great care, if at all, in
patients with congestive heart failure, severe renal insufficiency, and
in clinical states in which there exists edema with sodium retention. In patients with
diminished renal function, administration of 3% and 5% Sodium Chloride
Injection, USP may result in sodium retention.
|
| dailymed-instance:indicatio... |
3% and 5% Sodium
Chloride Injection, USP is indicated as a source of water and
electrolytes.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Sodium Chloride
|